BG105710A - 5ht1 antagonists for antidepressant therapy - Google Patents

5ht1 antagonists for antidepressant therapy

Info

Publication number
BG105710A
BG105710A BG105710A BG10571001A BG105710A BG 105710 A BG105710 A BG 105710A BG 105710 A BG105710 A BG 105710A BG 10571001 A BG10571001 A BG 10571001A BG 105710 A BG105710 A BG 105710A
Authority
BG
Bulgaria
Prior art keywords
antagonists
antidepressant therapy
compounds
antidepressant
therapy
Prior art date
Application number
BG105710A
Other languages
Bulgarian (bg)
English (en)
Inventor
Gene BRIGHT
Kishor DESAI
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG105710A publication Critical patent/BG105710A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG105710A 1998-12-28 2001-07-16 5ht1 antagonists for antidepressant therapy BG105710A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11395798P 1998-12-28 1998-12-28
PCT/IB1999/001772 WO2000039128A1 (en) 1998-12-28 1999-11-03 5ht1 antagonists for antidepressant therapy

Publications (1)

Publication Number Publication Date
BG105710A true BG105710A (en) 2002-02-28

Family

ID=22352526

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105710A BG105710A (en) 1998-12-28 2001-07-16 5ht1 antagonists for antidepressant therapy

Country Status (43)

Country Link
US (1) US6525196B1 (no)
EP (1) EP1140931B1 (no)
JP (1) JP2002533463A (no)
KR (1) KR100417506B1 (no)
CN (1) CN1332740A (no)
AP (1) AP2001002188A0 (no)
AR (1) AR024840A1 (no)
AT (1) ATE260278T1 (no)
AU (1) AU761711B2 (no)
BG (1) BG105710A (no)
BR (1) BR9916807A (no)
CA (1) CA2356985C (no)
CO (1) CO5150179A1 (no)
CR (1) CR6398A (no)
CZ (1) CZ291163B6 (no)
DE (1) DE69915113T2 (no)
DK (1) DK1140931T3 (no)
DZ (1) DZ2933A1 (no)
EA (1) EA003099B1 (no)
EE (1) EE04439B1 (no)
ES (1) ES2214892T3 (no)
GE (1) GEP20043227B (no)
GT (1) GT199900224A (no)
HR (1) HRP20010488A2 (no)
HU (1) HUP0104852A3 (no)
ID (1) ID30117A (no)
IL (1) IL143385A0 (no)
IS (1) IS5951A (no)
MA (1) MA26706A1 (no)
NO (1) NO20013215L (no)
NZ (1) NZ511964A (no)
OA (1) OA11742A (no)
PA (1) PA8486701A1 (no)
PE (1) PE20001234A1 (no)
PT (1) PT1140931E (no)
SK (1) SK9002001A3 (no)
TN (1) TNSN99218A1 (no)
TR (1) TR200101979T2 (no)
TW (1) TW523514B (no)
UA (1) UA62015C2 (no)
WO (1) WO2000039128A1 (no)
YU (1) YU44301A (no)
ZA (1) ZA200105041B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855729B2 (en) * 2001-02-20 2005-02-15 Timothy G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
CN100389115C (zh) * 2003-03-12 2008-05-21 辉瑞产品公司 吡啶氧基甲基和苯并异唑氮杂二环衍生物
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
BRPI0507250A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
CA2580034A1 (en) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds
US20070270430A1 (en) * 2004-09-10 2007-11-22 Pfzer Inc Methods of Treating Cognitive Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2021127391A1 (en) * 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
EP0763034A1 (en) * 1994-05-28 1997-03-19 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
NZ500252A (en) * 1997-04-18 2001-07-27 Smithkline Beecham P 6-(4-Methyl-piperazin-1-yl)-1H-indole derivatives useful as 5HT1A, 5HT1B and 5HT1D receptor antagonists
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1

Also Published As

Publication number Publication date
CN1332740A (zh) 2002-01-23
TR200101979T2 (tr) 2001-12-21
DE69915113D1 (de) 2004-04-01
AU6361499A (en) 2000-07-31
EA003099B1 (ru) 2002-12-26
DZ2933A1 (fr) 2004-03-15
PA8486701A1 (es) 2000-09-29
YU44301A (sh) 2004-07-15
DE69915113T2 (de) 2004-08-26
EE200100346A (et) 2002-12-16
EP1140931A1 (en) 2001-10-10
MA26706A1 (fr) 2004-12-20
OA11742A (en) 2005-05-13
TNSN99218A1 (fr) 2005-11-10
SK9002001A3 (en) 2002-04-04
HUP0104852A3 (en) 2002-12-28
NO20013215L (no) 2001-08-27
NZ511964A (en) 2003-08-29
ID30117A (id) 2001-11-08
AU761711B2 (en) 2003-06-05
KR100417506B1 (ko) 2004-02-05
DK1140931T3 (da) 2004-04-19
CZ20012386A3 (cs) 2002-02-13
TW523514B (en) 2003-03-11
BR9916807A (pt) 2001-10-23
AR024840A1 (es) 2002-10-30
NO20013215D0 (no) 2001-06-27
AP2001002188A0 (en) 2001-06-30
IL143385A0 (en) 2002-04-21
GT199900224A (es) 2001-06-15
HRP20010488A2 (en) 2002-08-31
WO2000039128A1 (en) 2000-07-06
CA2356985C (en) 2006-08-08
CZ291163B6 (cs) 2003-01-15
HUP0104852A2 (hu) 2002-05-29
EP1140931B1 (en) 2004-02-25
ES2214892T3 (es) 2004-09-16
PT1140931E (pt) 2004-05-31
ATE260278T1 (de) 2004-03-15
CA2356985A1 (en) 2000-07-06
CO5150179A1 (es) 2002-04-29
JP2002533463A (ja) 2002-10-08
KR20010092455A (ko) 2001-10-25
IS5951A (is) 2001-05-22
EE04439B1 (et) 2005-02-15
PE20001234A1 (es) 2000-11-07
GEP20043227B (en) 2004-04-26
US6525196B1 (en) 2003-02-25
EA200100517A1 (ru) 2001-12-24
ZA200105041B (en) 2002-06-20
CR6398A (es) 2004-03-24
UA62015C2 (en) 2003-12-15

Similar Documents

Publication Publication Date Title
BG106585A (en) Kinase inhibitors as therapeutic agents
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
AU1529402A (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
BG106013A (en) New compounds and compositions as protease inhibitors
BG103485A (en) Ketobanzamides as calpain inhibitors
MX9702865A (es) Agentes estrogenicos.
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BG106930A (en) Substituted phenyl-piperazine derivatives, their preparation and use
SE9901077D0 (sv) Novel use
IL140070A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
MXPA05010651A (es) Compuestos de pirazol.
DK1204659T3 (da) Serotonerge benzofuraner
MXPA05010650A (es) Pirazoles sustituidos.
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
MX9603199A (es) Antagonistas de receptores a endotelina.
ZA983231B (en) Substituted benzyloxyimino compounds.
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
BG105329A (en) N-substituted azabicycloheptane derivatives, production and use thereof
YU39603A (sh) Jedinjenja piperazinilpirazina kao antagonisti serotonin 5-ht2 receptora